Skip to main content
    G

    Gyre Therapeutics Inc. (GYRE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.56
    +0.17 (+3.87%)

    Market Cap: $480.49M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Gyre Therapeutics Inc. (GYRE) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Gyre Therapeutics (GYRE) has a market cap of $480.49M and an enterprise value of $438.85M. Its share count is up 17.01% from a year earlier. It kept -22.97% of revenue as net income over the last 12 months.

    Total Valuation

    Enterprise value is 8.67% below the market cap, as cash exceeds debt.

    Market Cap$480.49M
    Enterprise Value$438.85M
    Latest price (Nov 17, 2026)$4.56

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.63% in the quarter ended Sep 30, 2026 and grew 11.41% a year over 2 years.

    Shares Outstanding106.30M
    Shares Change (YoY)+17.01%
    Shares Change (QoQ)+5.63%
    Share Count Growth (2Y CAGR)+11.41%

    Valuation Ratios

    Sales and book value multiples are 4.0x and 4.5x. Its year-end P/S ranged from 1.0x to 35.8x from 2016 to 2025.

    P/S Ratio4.0x
    Forward P/S4.3x
    P/B Ratio4.5x
    P/TBV Ratio4.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 42.93% over 52 weeks and trades 26.45% below its 50-day average.

    Beta (1Y)1.63
    52-Week Change-42.93%
    1-Month Change-25.12%
    3-Month Change-36.22%
    6-Month Change-27.16%
    5-Year Change-64.88%
    10-Year Change-89.30%
    Total Return (1Y)-42.93%
    Total Return (3Y CAGR)-32.32%
    Total Return (5Y CAGR)+10.88%
    Return vs SPY (1Y)-52.11%
    Max Drawdown (1Y)-54.22%
    Max Drawdown (3Y)-86.49%
    Sharpe Ratio (1Y)-0.76
    Correlation with SPY (1Y)0.33
    50-Day Average$6.20
    200-Day Average$6.77
    52-Week Range$3.97 to $9.14
    RSI (14 Days)39.8
    Average Volume (20 Days)226.53K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 4.32x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio4.32x
    Quick Ratio3.89x
    Debt / Equity0.00x
    Interest Coverage-7.26x

    Returns and Efficiency

    Return on equity is -25.91% and return on assets is -13.90% over the last 12 months.

    Return on Equity (ROE)-25.91%
    Return on Assets (ROA)-13.90%
    ROA (5Y Average)-41.49%
    ROIC (5Y Average)13.90%
    Asset Turnover0.68x
    Inventory Turnover0.60x
    Receivables Turnover4.00x
    Cash Conversion Cycle598 days

    Scores

    GYRE has an Altman Z-Score of 7.98, in the safe zone above 2.99, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.

    Altman Z-Score7.98
    Altman Z ZoneSafe
    Piotroski F-Score3 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $121.75M over the last 12 months is up 8.36% from the 12 months before.

    Revenue$121.75M
    Revenue Growth (YoY)+8.36%
    Gross Profit$114.63M
    Operating Income-$25.12M
    Pretax Income-$25.48M
    Net Income-$27.97M
    Reported EPS (TTM)-$0.13

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 53.64% of the $201.25M in total assets.

    Cash and Equivalents$41.64M
    Total Debt$0
    Net Cash$41.64M
    Net Cash Per Share$0.39
    Working Capital$94.81M
    Shareholder Equity$107.95M
    Book Value Per Share$1.02
    Tangible Book Value$103.55M
    Tangible Book Per Share$0.97
    Total Assets$201.25M
    Total Liabilities$35.18M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.56M of capital spending, operating cash flow left -$24.72M of free cash flow.

    Operating Cash Flow-$23.16M
    Capital Expenditures$1.56M
    Free Cash Flow-$24.72M
    FCF Per Share-$0.23
    Depreciation and Amortization$3.28M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -20.63%.

    Gross Margin94.15%
    Operating Margin-20.63%
    Pretax Margin-20.93%
    Net Margin-22.97%
    FCF Margin-20.30%
    Gross Margin (5Y Average)76.47%

    Growth

    Revenue grew 4.46% a year over 3 years.

    Revenue Growth (3Y CAGR)+4.46%
    Revenue Growth (5Y CAGR)+40.96%
    Operating Income Growth (3Y CAGR)+7.67%

    Revenue and profit by year

    Dividends and Yields

    GYRE does not pay a dividend. Its free cash flow yield is -5.10%.

    FCF Yield-5.10%
    Buyback Yield0.00%
    Shareholder Yield0.00%

    Stock Splits

    The last split was a 1-for-15 reverse split on Oct 31, 2023.

    Last Split DateOct 31, 2023
    Split TypeReverse split
    Split Ratio1:15

    Peer Position

    Against 7 similar companies, GYRE has the 6th highest P/S.

    P/S Ratio4.0x vs 8.1x median
    Revenue Growth (Trailing 4 Quarters, YoY)+8.36% vs -39.51% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 12.36% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+12.36%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About GYRE

    What is GYRE's market cap?

    Gyre Therapeutics has a market cap of $480.49M. Its enterprise value, which adds debt and subtracts cash, is $438.85M.

    How many shares of GYRE are outstanding?

    Gyre Therapeutics has 106.30M shares outstanding. The count is up 17.01% from a year earlier.

    Does GYRE pay a dividend?

    No. Gyre Therapeutics does not pay a dividend.

    How much debt does GYRE have?

    Gyre Therapeutics has $0 of total debt and $41.64M of cash and equivalents, a net cash position of $41.64M.